Erdheim-Chester disease
| Erdheim-Chester disease | |
|---|---|
| Term | Erdheim-Chester disease |
| Short definition | Erdafitinib (ER-duh-FIH-tih-feather) A drug used to treat adults with urothelial cancer (a type of bladder or urinary tract cancer) that is locally advanced or has spread and certain Mutations (changes) in the tumor have FGFR3 or FGFR2 gene or a fusion gene involving these genes. It is used in patients whose cancer has gotten worse during or after treatment with at least one type of platinum chemotherapy. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Erdheim-Chester disease - (pronounced) (ERD-hime-CHEH-sterdih-ZEEZ) A very rare condition in which too many histiocytes (a type of white blood cell) build up in certain tissues and organs and damage them. Erdheim-Chester disease most commonly affects the long bones of the arms and legs, but can also affect the skin, lungs, heart, kidneys, brain, tissues behind the eyes, and the retroperitoneum (the back wall of the abdomen). Symptoms can range from mild to severe and life-threatening. Erdheim-Chester disease is most common in adults. It's a form of histiocytosis. Also called ECD
External links
- Medical encyclopedia article on Erdheim-Chester disease
- Wikipedia's article - Erdheim-Chester disease
This MedicineGPT article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski